Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328520 | 0.90 | MEN1 (0.31) | KMT2AMEN1CSNK2A2RAB9ACSNK2B | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.79 | GDA (0.48) | GDAPDPK1ALDH1A1XDHHPGD | |
| SCHEMBL533602 | 0.79 | MEN1 (0.39) | KMT2AMEN1CSNK2A2RAB9ACSNK2B | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.78 | GDA (0.47) | GDAPDPK1ALDH1A1XDHHPGD | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.78 | GDA (0.47) | GDAPDPK1ALDH1A1XDHHPGD | |
| SCHEMBL6545701 | 0.76 | GDA (0.34) | GDAPDPK1ALDH1A1XDHHPGD | |
| SCHEMBL11977311 | 0.76 | GDA (0.33) | GDAPDPK1ALDH1A1XDHHPGD | |
| SCHEMBL22700248 | 0.76 | GDA (0.33) | GDAPDPK1ALDH1A1XDHHPGD | |
| SCHEMBL5582500 | 0.76 | GDA (0.33) | GDAPDPK1ALDH1A1XDHHPGD | |
| SCHEMBL842437 | 0.76 | CSNK2A1 (0.36) | CSNK2A2CSNK2A1GDAPDPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | claimed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| EP-2097430-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[N- ACYL)AMIDOSELENOPHOSPHATE-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | Centrum Badan Molekularnych I Makromolekularnych Pan (PL) | 2009-09-09 | — | — | EP | claimed |
| WO-2009005382-A2 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2009-01-08 | — | — | WO | claimed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | claimed |
| WO-2008048128-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[(N- ACYL)AMIDOSELENOPHOSPHATE]-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2008-04-24 | — | — | WO | claimed |
| EP-0781138-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1997-07-02 | — | — | EP | claimed |
| EP-0533825-B1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | UNIV WAKE FOREST (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1996006620-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1996-03-07 | — | — | WO | claimed |
| EP-0533825-A4 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | — | 1993-06-02 | — | — | EP | claimed |
| EP-0533825-A1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES. | UNIV WAKE FOREST (US) | 1993-03-31 | — | — | EP | claimed |
| WO-1991019726-A1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | WAKE FOREST UNIVERSITY (US) | 1991-12-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | KMT2A 3050/4885MEN1 3276/4885CSNK2A2 898/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | KMT2A 973/4885MEN1 2749/4885CSNK2A2 2748/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | KMT2A 1435/4885MEN1 3388/4885CSNK2A2 3087/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | KMT2A 1435/4885MEN1 3388/4885CSNK2A2 3087/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | KMT2A 973/4885MEN1 2749/4885CSNK2A2 2748/4885 |
| US-20080293667-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | KMT2A 3530/4885MEN1 677/4885CSNK2A2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.